TCRX

TScan Therapeutics, Inc.
CAPPED RATING

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc. (TCRX) is rated D (1.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Revisions (F). The rating has held at D for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.4 / 5.0
D
Value
B-
Factor Score 3.0 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
F
Factor Score 0.4 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.3
EV / EBITDA -0.0
Rev Growth YoY -65.8%
Gross Margin 0.0%
Price Return 3M -79.5%
Price Return 12M -86.5%
Catalyst Signal 0.00
Market Cap $10.9M
TTM Revenue $7.1M
Price / Sales 1.5
ROE -95.8%

Historical Factor Score Progression

Held D for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) D (1.3) C- (2.1) F (0.4) F (0.0) D (1.4)
2026-11-08 B- (3.0) D (1.2) C- (2.0) F (0.4) F (0.0) D (1.3)
2026-11-01 B- (3.0) D (1.2) C- (2.1) F (0.4) F (0.0) D (1.3)
2026-10-25 B- (3.0) D (1.2) C- (2.1) F (0.5) F (0.0) D (1.3)
2026-10-18 B- (3.0) D (1.2) C- (2.1) F (0.5) F (0.0) D (1.3)
Page 1 of 5